Literature DB >> 2502678

Cystinuria and its treatment: 25 years experience at St. Bartholomew's Hospital.

A D Stephens1.   

Abstract

Cystinuria is an inherited condition affecting the active transport of the diamino acids cystine, ornithine, lysine and arginine across the renal tubule and the small intestine. The only clinical effect is the production of urinary tract stones and if these can be prevented the affected individuals can lead a normal life. In many people cystine stones can be dissolved and new stone formation prevented by a high fluid intake, but if this does not succeed regular treatment with penicillamine will do so. Although many side-effects have been described with penicillamine treatment it is rare for them to be severe enough to prevent its use in patients with cystinuria. Since the clinical effects of cystinuria can be prevented by either a high fluid intake or by penicillamine it is important to make the diagnosis in affected individuals as soon as possible and cystinuria should therefore be considered in all people (regardless of age) who form urinary stones.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502678     DOI: 10.1007/bf01800726

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  25 in total

1.  FURTHER OBSERVATIONS ON USE OF D-PENICILLAMINE IN CYSTINURIA.

Authors:  J C CRAWHALL; E F SCOWEN; R W WATTS
Journal:  Br Med J       Date:  1964-05-30

2.  TREATMENT OF CYSTINURIA.

Authors:  C E DENT; M FRIEDMAN; H GREEN; L C WATSON
Journal:  Br Med J       Date:  1965-02-13

3.  EFFECT OF PENICILLAMINE ON CYSTINURIA.

Authors:  J S KING; W H BOYCE
Journal:  Invest Urol       Date:  1965-05

4.  RECENT ADVANCES IN THE THERAPY OF CYSTINURIA.

Authors:  M LOTZ; J T POTTS; F C BARTTER
Journal:  Mil Med       Date:  1965-08       Impact factor: 1.437

5.  Studies on the treatment of cystinuria.

Authors:  C E DENT; B SENIOR
Journal:  Br J Urol       Date:  1955-12

6.  Phenotypes and genotypes in cystinuria.

Authors:  H HARRIS; U MITTWOCH; E B ROBSON; F L WARREN
Journal:  Ann Hum Genet       Date:  1955-08       Impact factor: 1.670

7.  New Agent in the Treatment of Cystinuria: N-acetyl-D-penicillamine.

Authors:  G S Stokes; J T Potts; M Lotz; F C Bartter
Journal:  Br Med J       Date:  1968-02-03

8.  The treatment of cystinuria with N-acetyl-D-penicillamine, a comparison with the results of D-penicillamine treatment.

Authors:  A D Stephens; R W Watts
Journal:  Q J Med       Date:  1971-07

9.  An analysis of the Z-dependence of photon and electron interactions.

Authors:  D R White
Journal:  Phys Med Biol       Date:  1977-03       Impact factor: 3.609

10.  Heterozygotes for cystinuria.

Authors:  J C Crawhall; E P Saunders; C J Thompson
Journal:  Ann Hum Genet       Date:  1966-03       Impact factor: 1.670

View more
  5 in total

1.  Urinary excretion of total cystine and the dibasic amino acids arginine, lysine and ornithine in relation to genetic findings in patients with cystinuria treated with sulfhydryl compounds.

Authors:  Erik Fjellstedt; Lotta Harnevik; Jan-Olof Jeppsson; Hans-Göran Tiselius; Peter Söderkvist; Torsten Denneberg
Journal:  Urol Res       Date:  2003-10-25

Review 2.  Prophylaxis of uric acid and cystine stones.

Authors:  B Hess
Journal:  Urol Res       Date:  1990

3.  A recessive contiguous gene deletion of chromosome 2p16 associated with cystinuria and a mitochondrial disease.

Authors:  R Parvari; I Brodyansky; O Elpeleg; S Moses; D Landau; E Hershkovitz
Journal:  Am J Hum Genet       Date:  2001-08-24       Impact factor: 11.025

4.  Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children.

Authors:  Ralph J DeBerardinis; Curtis R Coughlin; Paige Kaplan
Journal:  J Urol       Date:  2008-10-31       Impact factor: 7.450

5.  Extracorporeal shock wave lithotripsy for cystine urolithiasis in children: outcome and complications.

Authors:  Andjelka Slavković; Miladin Radovanović; Zlatko Sirić; Marina Vlajković; Vladisav Stefanović
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.